We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ:TXG) stands against the other genomics ...

CRSP CRISPR $57.47 EDIT Editas $11.70 TXG 10x Genomics $51.04 CRISPR Therapeutics (CRSP) While many biotech firms are now developing therapies that incorporate gene editing, CRISPR Therapeutics ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to ...

10x Genomics (TXG) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

On the business front, 10x Genomics settles with Bruker and Vizgen while Illumina sues Element Biosciences for patent infringement.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated ...

We are grateful to work with Arc and 10x Genomics to advance the development of these resources to accelerate scientific discovery and advance our understanding of biology’s complexity." ...

--10 x Genomics, Inc., a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. With these ...

ARK's flagship fund, ARKK, and its genomics-themed ARKG, bought a combined total of 187,338 shares of CRISPR Therapeutics AG, valued at approximately $7.59 million. This move underscores ARK's ...

Coupled with the invalidation of 10x Genomics’ 10,155,981 patent last year, Parse has now invalidated all claims that 10x Genomics asserts against Parse products, further reinforcing Parse’s ...